Loading...
Loading...
Aurinia Pharmaceuticals AUPH shares are trading lower on Thursday.
In an SEC filing on Wednesday night, the company announced it and Lonza have entered an exclusive agreement for a dedicated Voclosporin Manufacturing Capacity. The Monoplant is estimated to be operational in 2023.
Aurinia Pharmaceuticals shares were trading down 13.22% at $13.16 on Thursday at the time of publication. The stock has a 52-week high of $21.93 and a 52-week low of $9.83.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in